Evaluation of Undifferentiated Carcinoma from an Unidentified Primary Origin (Review Articles)
DOI:
https://doi.org/10.59675/U114Abstract
Cancers with an unidentified primary site at the start of treatment are classified as cancers with an unknown original primary site. Their prevalence among cancer patients is around 5%. One of the challenges in medicine is an approach to those patients. The requirement for the early detection of malignancies or palliative care are still problem in medicine. A strategy for their treatment should be created to avoid prolong hospital stays and testing that won't improve therapy or the prognosis for those sufferers.
It's crucial to identify individuals whose diseases have good prognoses since they may benefit greatly from targeted therapy, including longer survival. A targeted search for the main tumor in those patients is advised. However, for those patients who will effectively employ targeted therapies, the combination of a robust immunohistochemistry panel with novel molecular knowledge may enable the development of a specific management strategy
Downloads
References
Abbruzzese JL, Lenzi R, Raber MN, et al. The biology of unknown primary tumors. Semin Oncol. 1993;20:238–243.
Bugat R, Bataillard A, Lesimple T, et al. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002) Br J Cancer. 2003;89(suppl 1):S59–S66. DOI: https://doi.org/10.1038/sj.bjc.6601085
Bell CW, Pathak S, Frost P. Unknown primary tumors: establishment of cell lines, identification of chromosomal abnormalities, and implications for a second type of tumor progression. Cancer Res. 1989;49:4311–4315.
Bar-Eli M, Abbruzzese JL, Lee-Jackson D, et al. p53 gene mutation spectrum in human unknown primary tumors. Anticancer Res. 1993;13:1619–1623.
Hainsworth JD, Lennington WJ, Greco FA. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site.
Briasoulis E, Tsokos M, Fountzilas G, et al. Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study. Anticancer Res. 1998;18:1907–1914.
Naresh KN. Do metastatic tumours from an unknown primary reflect angiogenic incompetence of the tumour at the primary site?—a hypothesis. Med Hypotheses. 2002;59:357–360. DOI: https://doi.org/10.1016/S0306-9877(02)00221-9
Karavasilis V, Malamou-Mitsi V, Briasoulis E, et al. Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer. 2005;5:25. DOI: https://doi.org/10.1186/1471-2407-5-25
Hillen HF, Hak LE, Joosten-Achjanie SR, et al. Microvessel density in unknown primary tumors. Int J Cancer. 1997;74:81–85. DOI: https://doi.org/10.1002/(SICI)1097-0215(19970220)74:1<81::AID-IJC14>3.3.CO;2-I
Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004;100:1776–1785. DOI: https://doi.org/10.1002/cncr.20202
Rubin BP, Skarin AT, Pisick E, et al. Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur J Cancer Prev. 2001;10:77–82. DOI: https://doi.org/10.1097/00008469-200102000-00009
Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol. 1996;9:445–452.
Tan D, Li Q, Deeb G, et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol. 2003;34:597–604. DOI: https://doi.org/10.1016/S0046-8177(03)00180-1
Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol. 2002;55:662–668. DOI: https://doi.org/10.1136/jcp.55.9.662
Ordonez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol. 2006;19:34–48. DOI: https://doi.org/10.1038/modpathol.3800471
Lau SK, Prakash S, Geller SA, et al. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol. 2002;33:1175–1181. DOI: https://doi.org/10.1053/hupa.2002.130104
Maitra A, Murakata LA, Albores-Saavedra J. Immunoreactivity for hepatocyte paraffin 1 antibody in hepatoid adenocarcinomas of the gastrointestinal tract. Am J Clin Pathol. 2001;115:689– 694. DOI: https://doi.org/10.1309/5C2C-FP3H-GE7Q-2XJ5
Clark JW, Snell L, Shiu RP, et al. The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis. Br J Cancer. 1999;81:1002–1008. DOI: https://doi.org/10.1038/sj.bjc.6690799
Wick MR, Lillemoe TJ, Copland GT, et al. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. HumPathol. 1989;20:281–287. DOI: https://doi.org/10.1016/0046-8177(89)90137-8
Kaufmann O, Deidesheimer T, Muehlenberg M, et al. Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Histopathology. 1996;29:233–240. DOI: https://doi.org/10.1111/j.1365-2559.1996.tb01396.x
Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol. 2000;113:683–687. DOI: https://doi.org/10.1309/PYQC-17CB-063T-Q07J
Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol. 2003;27:1–10. DOI: https://doi.org/10.1097/00000478-200301000-00001
Barbareschi M, Murer B, Colby TV, et al. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am J Surg Pathol. 2003;27:141–149. DOI: https://doi.org/10.1097/00000478-200302000-00001
Milovic M, Popov I, Jelic S. Tumor markers in metastatic disease from cancer of unknown primary origin. Med Sci Monit. 2002;8:MT25–MT30.
Pavlidis N, Kalef-Ezra J, Briassoulis E, et al. Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med Pediatr Oncol. 1994;22:162–167. DOI: https://doi.org/10.1002/mpo.2950220303
Motzer RJ, Rodriguez E, Reuter VE, et al. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J Clin Oncol. 1995;13:274–282. DOI: https://doi.org/10.1200/JCO.1995.13.1.274
Pantou D, Tsarouha H, Papadopoulou A, et al. Cytogenetic profile of unknown primary tumors: clues for their pathogenesis and clinical management. Neoplasia.
McMillan JH, Levine E, Stephens RH. Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown primary site. A retrospective study. Radiology. 1982;143:143– 146. DOI: https://doi.org/10.1148/radiology.143.1.7063718
Abbruzzese JL, Abbruzzese MC, Lenzi R, et al. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995;13:2094–2103. DOI: https://doi.org/10.1200/JCO.1995.13.8.2094
Koch WM, Bhatti N, Williams MF, et al. Oncologic rationale for bilateral tonsillectomy in head and neck squamous cell carcinoma of unknown primary source. Otolaryngol Head Neck Surg. 2001;124:331–333. DOI: https://doi.org/10.1067/mhn.2001.114309
Randall DA, Johnstone PA, Foss RD, et al. Tonsillectomy in diagnosis of the unknown primary tumor of the head and neck. Otolaryngol Head Neck Surg. 2000;122:52–55. DOI: https://doi.org/10.1016/S0194-5998(00)70143-4
Johansen J, Eigtved A, Buchwald C, et al. Implication of 18F-fluoro-2-deoxy-D-glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck: a Danish cohort study. Laryngoscope. 2002;112:2009–2014. DOI: https://doi.org/10.1097/00005537-200211000-00018
Regelink G, Brouwer J, de Bree R, et al. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imaging. 2002;29:1024– 1030. DOI: https://doi.org/10.1007/s00259-002-0819-0
Jungehulsing M, Scheidhauer K, Damm M, et al. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg. 2000;123:294–301. DOI: https://doi.org/10.1067/mhn.2000.104807
Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer. 2004;101:2641– 2649. DOI: https://doi.org/10.1002/cncr.20687
Alberini JL, Belhocine T, Hustinx R, et al. Whole-body positron emission tomography using fluorodeoxyglucose in patients with metastases of unknown primary tumours (CUP syndrome) Nucl Med Commun. 2003;24:1081–1086. DOI: https://doi.org/10.1097/00006231-200310000-00008
Gutzeit A, Antoch G, Kuhl H, et al. Unknown primary tumors: detection with dual-modality PET/CT—initial experience. Radiology. 2005;234:227–234. DOI: https://doi.org/10.1148/radiol.2341031554
Olson JA, Jr, Morris EA, Van Zee KJ, et al. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol. 2000;7:411–415. DOI: https://doi.org/10.1007/s10434-000-0411-4
Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA. 2001;98:13790–13795.
Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA. 2001;98:13790–13795. DOI: https://doi.org/10.1073/pnas.191502998
Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11:3766–3772. DOI: https://doi.org/10.1158/1078-0432.CCR-04-2236
Dennis JL, Vass JK, Wit EC, et al. Identification from public data of molecular markers of adenocarcinoma characteristic of the site of origin. Cancer Res. 2002;62:5999–6005.
Su AI, Welsh JB, Sapinoso LM, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. 2001;61:7388–7393.
Tothill RW, Kowalczyk A, Rischin D, et al. An expression- based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res. 2005;65:4031–4040. DOI: https://doi.org/10.1158/0008-5472.CAN-04-3617
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Academic International Journal of Medical Update
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
